172 related articles for article (PubMed ID: 22838949)
21. Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
Aksoy P; Zhu MJ; Kalari KR; Moon I; Pelleymounter LL; Eckloff BW; Wieben ED; Yee VC; Weinshilboum RM; Wang L
Pharmacogenet Genomics; 2009 Aug; 19(8):567-76. PubMed ID: 19623099
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
Gilbert JA; Salavaggione OE; Ji Y; Pelleymounter LL; Eckloff BW; Wieben ED; Ames MM; Weinshilboum RM
Clin Cancer Res; 2006 Mar; 12(6):1794-803. PubMed ID: 16551864
[TBL] [Abstract][Full Text] [Related]
23. High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C; Ciccolini J; Mercier C; Boyer JC; Polge A; Lallemant B; Mouzat K; Lumbroso S; Brouillet JP; Evrard A
Ther Drug Monit; 2010 Feb; 32(1):53-60. PubMed ID: 20010457
[TBL] [Abstract][Full Text] [Related]
24. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
[TBL] [Abstract][Full Text] [Related]
25. Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Attia F; Fathy S; Anani M; Hassan A; Attia F; Ibrahim G; Elazab M
J Clin Lab Anal; 2020 Nov; 34(11):e23457. PubMed ID: 32671914
[TBL] [Abstract][Full Text] [Related]
26. Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
Kocabas NA; Aksoy P; Pelleymounter LL; Moon I; Ryu JS; Gilbert JA; Salavaggione OE; Eckloff BW; Wieben ED; Yee V; Weinshilboum RM; Ames MM
Drug Metab Dispos; 2008 Sep; 36(9):1951-9. PubMed ID: 18556440
[TBL] [Abstract][Full Text] [Related]
27. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Lee SY; Im SA; Park YH; Woo SY; Kim S; Choi MK; Chang W; Ahn JS; Im YH
Eur J Cancer; 2014 Mar; 50(4):698-705. PubMed ID: 24361227
[TBL] [Abstract][Full Text] [Related]
28. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
[TBL] [Abstract][Full Text] [Related]
29. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
30. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.
Li L; Schaid DJ; Fridley BL; Kalari KR; Jenkins GD; Abo RP; Batzler A; Moon I; Pelleymounter L; Eckloff BW; Wieben ED; Sun Z; Yang P; Wang L
Pharmacogenet Genomics; 2012 Feb; 22(2):105-16. PubMed ID: 22173087
[TBL] [Abstract][Full Text] [Related]
32. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
34. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
Sigmond J; Honeywell RJ; Postma TJ; Dirven CM; de Lange SM; van der Born K; Laan AC; Baayen JC; Van Groeningen CJ; Bergman AM; Giaccone G; Peters GJ
Ann Oncol; 2009 Jan; 20(1):182-7. PubMed ID: 18701427
[TBL] [Abstract][Full Text] [Related]
36. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
Pharmacogenet Genomics; 2012 Jan; 22(1):58-68. PubMed ID: 22134350
[TBL] [Abstract][Full Text] [Related]
37. Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Mercier C; Dahan L; Ouafik L; André N; Ciccolini J
Eur J Clin Pharmacol; 2010 Sep; 66(9):959-60. PubMed ID: 20563566
[No Abstract] [Full Text] [Related]
38. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
[TBL] [Abstract][Full Text] [Related]
40. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]